Screening in Primary Care of Advanced Liver Fibrosis in NAFLD and/or Alcoholic Patients (IMPROVE Study)
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Alcohol-Related Disorder
- Liver Fibrosis
- NAFLD
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: prospective diagnostic study in primary care. Evaluation of a simple blood test (e-LIFT) for the diagnosis of advanced liver fibrosis. Reference for advanced liver diagnosis : composite criteria : Elastometry between 8 kPa and 15 kPa and histologic evaluation of fibrosis ? F3 (NASH CRN ) OR Elastometry ? 15 kPa Masking: None (Open Label)Primary Purpose: Diagnostic
Participation Requirements
- Age
- Between 40 years and 75 years
- Gender
- Both males and females
Description
eLIFT, is a new blood fibrosis test specifically dedicated for general practitioners with simple parameters and easy "by head" calculation. Using the recommended cut-offs (eLIFT ?8), eLIFT sensitivity was 86%. This result position eLIFT an as interesting tool for the screening of advanced liver fibr...
eLIFT, is a new blood fibrosis test specifically dedicated for general practitioners with simple parameters and easy "by head" calculation. Using the recommended cut-offs (eLIFT ?8), eLIFT sensitivity was 86%. This result position eLIFT an as interesting tool for the screening of advanced liver fibrosis in large populations. As our preliminary results come from very selected patients, i.e. patients from tertiary centres who underwent a liver biopsy, we now need to evaluate in the real condition of primary care setting whether the use of eLIFT will help general practitioners to screen advanced liver fibrosis in their asymptomatic NAFLD and alcoholic patients.
Tracking Information
- NCT #
- NCT04146636
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon